Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Cardiology
•
Preventive Cardiology
How do you decide between IL-1 inhibitors, azathioprine, and IVIG for steroid-dependent recurrent/incessant pericarditis?
Related Questions
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
Are there any ongoing clinical trials related to endothelial dysfunction and accelerated or premature CAD that patients might be able to enroll in nationwide?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
When would you consider ordering additional testing such as hs-CRP, lipoprotein A levels, or CAC scoring to further risk stratify otherwise healthy pre-menopausal women with a prior history of pregnancy-related hypertension, diabetes, or premature births?
When would you consider long-term cardiac monitoring to look for atrial fibrillation in patients with mitral stenosis given their baseline elevated risk for atrial fibrillation and thrombosis?
Would it be reasonable to consider switching from a high intensity statin therapy to PCSK9 inhibitor vs. adding adjunct lipid lowering medications for a patient with known coronary artery calcifications, LDL in the mid-100 range pre-statin with worsening A1C levels?
What is your approach to medical management for cocaine-induced acute MI, and threshold to consider referral for coronary angiography in the setting of a markedly elevated troponin and LV systolic dysfunction?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
